Bios Health Group has entered the life sciences market. This new company entity is a strategic partner providing solutions for life science companies and investors. It offers strategies to attract funding, optimize clinical development, and create effective commercial strategies. Bios Health Group also serves as a venture partner providing investor preparation for Bbotech companies seeking investment funding and access to venture funds through its investor networks.
Bios Health Group Chief Executive Officer, Zizi Uzezi Imatorbhebhe, MBA MS PMP® said in a press release, "We are thrilled to bring this comprehensive suite of end-to-end solutions to biotech and life science companies. Our strategic approach involves engagement with venture capitalists and investors, effectively addressing the funding gap that often impedes early-stage biotech companies from accessing critical financial resources required to realize their innovative concepts. Additionally, we provide established companies with proven commercial strategies to launch new products and expand their market presence."
Bios Health Group offers four strategic solutions:
Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies. (2023, August 15). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.